













Abstracts / Biol Blood Marrow Transplant 19 (2013) S109eS128S118range 10 e 22, were enrolled (Feb 2007 e July 2012). All had
hepatomegaly. Median ferritin level was 3,500 ng/mL. All of
them received hydroxyurea (20 mg/kg/day) for at least 6
months. They also received sequential immunoablative
regimen consisted with 2 monthly cycles of ﬂudarabine 40
mg/m2 and dexamethasone 25 mg/m2 x 5 days prior to
conditioning regimen. The conditioning regimen consisted
with busulfan 130 mg/m2 x 4 days, ﬂudarabine 35 mg/m2 x 6
days and ATG 6 mg/kg. GVHD prophylaxis consisted with FK
506 or cyclosporine and MMF. All of them received periph-
eral blood stem cells with a target dose of CD34þ10 x 106
cells/kg. Eleven patients received matched related and 4
receivedmatched unrelated donor stem cells. Median time of
neutrophil and platelet engraftment was day þ10 and þ 15
respectively. Three patients had mild VOD. Four patients had
grade II-IV and none had grade III-IV GVHD. Five patients had
mild chronic GVHD which subsequently was resolved. All 15
patients achieved full (100%) donor chimerism at day þ30
and these chimerisms were sustainable. Overall and disease
free survival rates were 91.2 % (95%CI:50-96). No rejection
was observed. One patient died from cerebellar hemorrhage.
We suggest that our sequential immunoblative regimen prior
to conditioning regimen is a key factor for this favorable
outcome in these difﬁcult patients. We also proved that T cell
proliferation assay (stimulationwith PHA) was suppressed in
all patients after 2 cycles of sequential immunoablative
regimen. This could explain the immunoablative concept in
our study. Our novel approach may be suitable for transplant
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*Performed at date of last follow-up from peripheral blood.
yDeath Day 47 Pneumonia.
zRe-transplanted with haploidentical donor.18
Nicord Expanded Hematopoietic Progenitor Cells (HPC)
Are Capable of Outcompeting the Unmanipulated (UM)
Cord Blood Unit and of Prolonged Myeloid and Lymphoid
Engraftment Following Myeloablative Dual Umbilical
Cord Blood (UCB) Transplantation
Mitchell E. Horwitz 1, Patrick J. Stiff 2, Nelson J. Chao 3,
David Rizzieri 3, Gwynn Long 1, Keith Sullivan 3,
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Carolyn McDonald 1, Steven Wease 4, David Snyder 5,
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Etty Friend 5, Joanne Kurtzberg 6, Tony Peled 5. 1 Division of
Hematologic Malignancies and Cellular Therapy, Duke
University Medical Center; 2 Loyola Univ Medical Center,
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Cellular Therapy, Duke University Medical Center, Durham, NC;
4 EMMES Corporation, Rockville, MD; 5 Gamida Cell Ltd.,
Jerusalem, Israel; 6 Pediatric Blood and Marrow Transplant
Program, Duke University Medical Center, Durham, NC
Human transplantation of expanded HPCs resulting in
durable, robust donor myeloid and T-cell engraftment has
yet to be reported. A pilot study of myeloablative dual UCB
transplantation where one UCB unit is expanded ex vivo
using NiCord technology has completed accrual. The NiCord
UCB graft consisted of an expanded CD133þ and an unex-
panded CD133- T-cell fraction. HPCs were expanded for 21
days in media containing cytokines supplemented with
nicotinamide (NAM). All patients were conditioned with TBI
(1350cGy), ﬂudarabine 160mg/m2 cyclophosphamide
120mg/kg (n¼2). GvHD prophylaxis consisted of tacrolimus
and MMF. Eleven patients (med. age 45; range 21-61) with
high-risk malignancies received NiCord and an UM graft
(Table). Both units were comparably HLA-matched with the
recipient; 4/6 (n¼7), 5/6 (n¼3) or 6/6 (n¼1) vs. 4/6 (n¼8), 5/6
HLA (n¼3), respectively. However, the UM unit containeda larger pre-cryopreserved cell dose (3 x 107/kg [range 1.9-
3.9] vs. 2.5 x 107/kg [range 1.7-3.8]). After expansion
(CD133þ fraction), NiCord contained a median TNC and
CD34þ cell dose of 2.7 x 107/kg (1.0-6.4) and 3.5 x 106/kg
(0.9-18.3), respectively. The NiCord T-cell dose was
substantially smaller than the UM graft.
Results: Eight patients engrafted with NiCord (one of which
is a mixed donor chimera) and twowith the UM graft (Table).
One patient experienced primary graft failure. The median
time to neutrophil engraftment was 12.5 days (7-26) for the
entire cohort, and 10.5 (7-18) days for those engrafting with
NiCord. Three patients experienced grade I/II acute GvHD.
There were no cases of Grade III/IV acute GvHD. No safety
concerns were raised. The estimated 100-day treatment-
related mortality is 10%. With a median follow-up of 8
months, the progression-free and overall survival are both
90%.
Conclusion: NiCord expanded HPC’s are capable of out-
competing those from the UM unit and predominate in the
majority of patients. NiCord expanded HPC’s reduce the time
to hematopoietic recovery and are capable of long term (>22
months) neutrophil and T-cell engraftment. Stem cell
transplantation using NiCord is feasible, and may provide
a potent cord blood graft enabling transplantation of a single
expanded unit, without co-infusion of UM cells.19
Trends in the Incidence and Spectrum of Organisms
Responsible for Bacteremia After Allogeneic Stem Cell
Transplantation Using Two Different Prophylactic
Strategies: A 12-Year Experience At Memorial Sloan-
Kettering Cancer Center
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The present study aimed to analyze changes in the inci-
dence of and pathogens associated with bacteremias and the
development of microbial resistance during two different
prophylactic strategies in adult recipients of allogeneic
hematopoietic stem cell transplantation (HSCT) at Memorial
Sloan-Kettering Cancer Center.
Methods: This was an observational cohort study of 1,138
consecutive adult HSCT from 2000-2011. Bacteremias
occurring from day -7 to þ100 post HSCT were entered into
a computerized database. Beginning November 2005, all
patients except those receiving nonmyeloablative-condi-
tioning regimens were given vancomycin prophylaxis from
day -2 through day þ7. Fluoroquinolone (FQ) prophylaxis
was initiated in November 2006. We compared the overall
incidence of bacteremia, changing spectrum of the organ-
isms, and the resistance pattern between 2000-2005 (period
A) and 2006-2011 (period B).
Results: During the study period, 312 (28%) patients had 363
bacteremic episodes with 392 pathogens isolated. The
median onset of ﬁrst episode was 7 days post transplant, and
62% of the episodes occurred before neutrophil recovery. The
incidence of gram-positive bacteria (GPB) and gram-negative
rod (GNR) bacteremia was 19% and 15%, respectively.
Enterococcus faecium was the most commonly isolated GPB
(46%), followed by viridans group streptococci (17%), while
Escherichia coli was the most common GNR (26%). Vanco-
mycin-resistant enterococci comprised the majority of
enterococcal isolates (81% in period A and 90% in period B,Etiology of bacteremias pre- and post-antibiotic prophylaxis








N (%)* N (%)*
Gram positive bacteria 219
Coagulase-negative
staphylococci
21 (5.3) 32 (4.3) 53
Enterococcus faecium 36 (9.1) 64 (8.6) 100
Enterococcus faecalis 7 (1.8) 5 (0.7) 12
Viridans group
streptococci
31 (7.8) 6 (0.8) 37
Staphylococcus aureus 5 6 11
Corynebacterium JK 3 1 4
Bacillus spp. 1 0 1
Gram-negative bacteria 173
Enterobacteriaceae total 37 (9.3) 79 (10.6) 116
Escherichia coli 16 29 45
Klebseilla spp. 14 29 43
Enterobacter spp. 7 13 20
Serratia spp. 0 8 8
Non-fermenter GNR 16 (4) 25 (3.4) 41




Acinetobacter spp. 8 7 15
Fusobacterium spp. 6 2 8
Other GNRy 5 4 9
Total number of allo-HSCT 397 742 1138
* % number of organisms/total allo-HSCT recipients during that period.
y Neisseria spp 1, Bacteroidesfragilis 1, Achromobacter xylosoxidans 1,
Hemophilus parainﬂuenzae 1, Roseomonas spp. 1, Proteus mirabilis 1,
Moraxella spp 1, Leuconostoc spp. 1. Clostridium spp 1.P¼0.2011). Eighty-nine percent of the Viridans streptococcal
bacteremias (VSB) and 60% of the GNR bacteremias occurred
before neutrophil recovery. The overall incidence of bacter-
emia decreased signiﬁcantly from 32% in period A to 25% in
period B (P¼0.005). Viridans group streptococci comprised
31 of 168 (18%) organisms in period A compared to 6 of 224
(3%) in period B (P <0.0001). The incidence of enterococcal
bacteremia remained stable (11% versus 9%, p¼0.47). There
was no change in the incidence of GNR bacteremia during
the study period (17% in 2000 e 2006 and 14% in 2007 e
2011, p¼0.27). Among GNR, the rate of FQ resistance was 39%
and was unchanged between the two periods.
Conclusions: Duringa12-yearperiod, theoverall incidenceof
bacteremia decreased. The decrease was mainly due to the
dramatic decrease of VSB after institution of vancomycin for
prophylaxis. The incidence of GNR and VRE bacteremia
remained stable in the periods pre and post FQ prophylaxis.
The rate of FQ resistance among GNR was also unchanged in
the two periods. Continued surveillance is necessary to iden-
tify changes in local epidemiology, to reevaluate prophylactic
regimens and to guide new empiric-therapy schemes.
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BK Virus Subtype III Is Associated with Hemorrhagic
Cystitis After Allogeneic Hematopoietic Stem Cell
Transplantation
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Yoshikane Kikushige 1, Seido Oku 1, Takuro Kuriyama 1,
Yasuo Mori 1, Tsuyoshi Muta 1, Katsuto Takenaka 1,
Hiromi Iwasaki 6, Tomohiko Kamimura 5, Tetsuya Eto 4,
Takanori Teshima 6, Nobuyuki Shimono 2, Jun Hayashi 2,
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Background: BK virus (BKV) associated hemorrhagic cystitis
(HC) following allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT) has been increasingly reported.
However, there is less information about diagnosis and
treatment. The purpose of this study is to clarify the signif-
icance of viral subtypes in the pathogenesis of BKV-HC in
Japanese subjects.
Methods: Urinary decoy cells compatible with BKV reac-
tivation were examined in patients every week as post-HSCT
screening. The real-time quantitative PCR (qPCR) for BKV and
adenovirus (ADV) were performed on urine samples when
patients developed HC and/or had positive decoy cells. BKV
subtypes (I-IV) were determined through viral DNA
sequencing in each patients with positive BKV qPCR (>2x102
copies/ml).
Results: A total of 84 allo-HSCTs were performed between
July 2010 and April 2012 (Figure 1). Of the 31 patients (pts)
whom only BKV reactivation was detected, 11 developed HC.
BKV subtypes were determined in these 31 pts (Ia: n¼2, Ib-1:
n¼2, Ic: n¼16, III: n¼8, and IVb-1: n¼3). Interestingly, BKV
subtype III was found in 6 of 11 pts with BKV-HC. There was
no direct correlation between development of HC and viral
load (HC vs No-HC: 1.3 vs 2.0x107 copies/mL, p¼0.86). In
addition, there was no signiﬁcant association between HC
and other risk factors such as age (p¼0.45), disease status
